Mapping the HER-family landscape in advanced urothelial carcinoma Authors: A Moradi, K Shah, A Tripathi Published: 2026 The human epidermal growth factor receptor (HER) family, comprising epidermal growth factor receptor (EGFR)/HER1, HER2, HER3, and HER4, has long been implicated in oncogenic signaling across several solid tumors. Among these receptors, HER2 has been the most successfully translated into a therapeutic target, with agents such as trastuzumab and trastuzumab deruxtecan (T-DXd) markedly improving outcomes in HER2-positive breast and gastroesophageal cancers.1 In urothelial carcinoma (UC), however, clinical translation of HER-directed therapy has been more complex. Although HER-targeted therapies have been explored for many years, early approaches, including maintenance lapatinib in HER1/HER2-positive metastatic bladder cancer, failed to establish a clear therapeutic role.2 The emergence of antibody–drug conjugates (ADCs) has renewed interest in HER receptors as drug-delivery targets rather than solely as oncogenic drivers. HER2 remains the leading target in UC, supported by the activity of T-DXd and disitamab vedotin (DV) in HER2-expressing disease.3,4 HER-directed ADC development is also expanding beyond HER2, as seen in the ongoing randomized phase II-III IZABRIGHT-Bladder01 trial of izalontamab brengitecan, an EGFR × HER3 bispecific ADC, in advanced UC after progression on immunotherapy.5 These advances make a broader evaluation of HER-family biology beyond HER2 increasingly relevant. In this issue, Coca Membribes et al.6 provide a detailed assessment of HER1-4 protein and RNA expression in advanced UC using tumor tissue from the screening population of the randomized LaMB trial.2 Among 446 tumors evaluable for HER1 and HER2 immunohistochemistry (IHC), expression was detected in 89% and 80% of cases, respectively. HER3 and HER4 were also frequently expressed in smaller evaluable subsets, at 77% and 75%, respectively. High-level expression (IHC 3+) was less common, ranging from 12% for HER2 to 34% for HER1. Among tumors with complete HER1-4 IHC data, nearly all expressed at least one HER-family receptor, and 61% coexpressed all four receptors, although concurrent high-level coexpression was uncommon. Distinct molecular subtype-specific patterns were observed, with HER2 expression enriched in luminal tumors and HER1/HER3 enriched in basal tumors, consistent with the broader molecular heterogeneity of UC that has been previously described.7,8 Although exploratory associations were seen between HER expression and platinum-based chemotherapy response, HER-family expression was not associated with overall survival. Together, these findings broaden the potential HER-directed therapeutic landscape in UC, while underscoring that receptor expression alone is insufficient as a prognostic or predictive biomarker. This work suggests that HER expression in UC should be considered as a broader receptor landscape rather than a HER2-centric biomarker. In the study by Coca Membribes et al.,6 HER-family receptors were frequently expressed and coexpressed, although high-level expression was lower. This pattern is particularly relevant in the ADC era, where surface antigen expression may enable cytotoxic payload delivery even when HER signaling is not the dominant oncogenic driver itself. Clinical data with T-DXd and DV have demonstrated meaningful activity in HER2-expressing UC, and the phase III RC48-C016 trial showed improved outcomes with DV plus toripalimab compared with chemotherapy in previously untreated HER2-expressing disease (HER2 IHC 1-3+).3,4,9 However, the relationship between HER expression and therapeutic benefit remains unsettled. Although HER2 protein expression and ERBB2 amplification have been explored, their ability to predict ADC sensitivity is less well established than in breast or gastric cancer. Reported rates of HER2 positivity vary substantially across studies, likely reflecting differences in tissue source, assay methods, and scoring criteria.10,11 Thus, Coca Membribes et al.6 strengthen the rationale for HER-directed drug development in UC, while highlighting the need to validate which expression patterns, thresholds, and tissue contexts predict clinical benefit. For ADCs, activity likely depends not only on antigen presence but also on antigen density and distribution, receptor internalization, linker stability, payload potency, and bystander effects.12 The study also has important implications beyond HER2-directed therapy. HER1/HER3 coexpression was among the most frequent patterns observed, which is timely given the emergence of HER1/HER3-targeted bispecific ADCs. BL-B01D1, known as izalontamab brengitecan, is an EGFR × HER3 bispecific ADC that has shown preliminary antitumor activity in heavily pretreated solid tumors and is now being evaluated in advanced UC, including in the randomized IZABRIGHT-Bladder01 trial (NCT07106762).5,13 These developments support the translational relevance of the receptor coexpression patterns reported here. However, they also raise important questions. Future HER-directed ADC trials must determine whether benefit is best predicted by expression of a single target, dual-receptor coexpression, molecular subtype, or integrated biomarkers combining protein expression with RNA and genomic features. Although this manuscript was not designed to define such treatment-selection criteria, it provides an important biological framework for their prospective evaluation. Several limitations should temper the interpretation of these findings. HER3 and HER4 were assessed in relatively small subsets and the analyses of clinical outcomes were exploratory. The IHC thresholds used to define positivity and high expression were adapted from existing HER scoring approaches but UC-specific thresholds remain incompletely established. In addition, the source of analyzed tissue, including primary compared with metastatic site and timing relative to systemic therapy, may influence HER expression and coexpression patterns. Spatial and temporal heterogeneity are particularly relevant in UC, where HER2 expression can vary within tumors and between primary, recurrent, and metastatic sites.14 These considerations will become increasingly important as HER-directed strategies expand beyond HER2 toward broader HER-family and dual-receptor approaches. Overall, this study provides one of the most comprehensive characterizations of HER1-4 expression and coexpression in advanced UC. The findings support a broader view of HER biology as ADCs reshape the therapeutic landscape of UC. The next step is to determine which expression patterns, thresholds, and tissue contexts predict benefit from specific HER-directed agents. Future trials should prospectively integrate HER-family IHC, RNA expression, ERBB genomic alterations, molecular subtype, tissue source, and clinical response to develop clinically useful biomarker strategies. HER-family expression in UC is no longer simply a biological observation; it is an emerging framework for therapeutic development. Whether it can be translated into a reliable biomarker for treatment selection remains the key question. Acknowledgments Funding None declared. Disclosure AT reports consulting/advisory roles with Gilead Sciences, Pfizer, Deka Biosciences, and SystImmune outside the submitted work; an immediate family member participates in a speakers’ bureau for Sanofi and Janssen. No disclosures were reported by AM or KS. References